Inhaled drug developer MannKind Corporation announced that the company has expanded its capacity for commercial manufacturing of highly potent dry powder formulations at its facility in Danbury, Connecticut, USA. The new manufacturing suite includes bulk powder formulation and filling for high potency powders such as epinephrine, the company said.
According to Mannkind, the expansion of the high potency capacity is “in alignment with MannKind’s strategic partnerships.” As early as 2016, the company cited epinephrine as a top candidate in its pipeline; the company’s website currently shows epinephrine still in pre-clinical development.
In April 2019, MannKind said that it had received its first milestone payment from United Therapeutics for development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial hypertension. United Therapeutics is also partnered with MannKind on an “undisclosed Technosphere formulation.” MannKind is also developing cannabidiol and dronabinol formulations in partnership with Receptor Life Sciences.
MannKind Chief Technology Officer Joe Kocinsky commented, “This expansion will allow us to utilize more fully the capacity of our world class, FDA-approved manufacturing facility for dry powder inhalation products. We are also pursuing opportunities to utilize our lyophilization capacity to fulfill the needs of our industry and drug development partners.”
Read the MannKind Corporation press release.
